The biology of Huntington's disease

Handbook of Clinical Neurology

Volumn 89, Issue , 2008, Pages 619-629

  Saudou, Frédéric ^a   Humbert, Sandrine ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; POLYGLUTAMINE;

BIOLOGICAL MODEL; BIOLOGY; CELL DEATH; GENETICS; HUMAN; HUNTINGTON CHOREA; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION;

BIOLOGY; CELL DEATH; HUMANS; HUNTINGTON DISEASE; MODELS, BIOLOGICAL; NEURONS; PEPTIDES; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 66049127093     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)01257-2     Document Type: Review

References (131)

1. Ahmad F.J., Echeverri C.J., Vallee R.B., et al. Cytoplasmic dynein and dynactin are required for the transport of microtubules into the axon. J Cell Biol 140 (1998) 391-401
2. Andrew S.E., Goldberg Y.P., and Hayden M.R. Rethinking genotype and phenotype correlations in polyglutamine expansion disorders. Hum Mol Genet 6 (1997) 2005-2010
3. Arrasate M., Mitra S., Schweitzer E.S., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
4. Ashcroft M., Stephens R.M., Hallberg B., et al. The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth. Oncogene 18 (1999) 4586-4597
5. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001) 1552-1555
6. Bennett E.J., Bence N.F., Jayakumar R., et al. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 17 (2005) 351-365
7. Bertolotti A., Zhang Y., Hendershot L.M., et al. Dynamic interaction of bip and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2 (2000) 326-332
8. Bezprozvanny I., and Hayden M.R. Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun 322 (2004) 1310-1317
9. Bizat N., Hermel J.M., Boyer F., et al. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J Neurosci 23 (2003) 5020-5030
10. Boutell J.M., Thomas P., Neal J.W., et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 8 (1999) 1647-1655
11. Bowman A.B., Yoo S.Y., Dantuma N.P., et al. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 14 (2005) 679-691
12. Cattaneo E., Rigamonti D., Goffredo D., et al. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 24 (2001) 182-188
13. Choo Y.S., Johnson G.V., MacDonald M., et al. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13 (2004) 1407-1420
14. Colin E., Regulier E., Perrin V., et al. Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 21 (2005) 1478-1488
15. Cornett J., Cao F., Wang C.E., et al. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 37 (2005) 198-204
16. Cui L., Jeong H., Borovecki F., et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127 (2006) 59-69
17. Davies S.W., Turmaine M., Cozens B.A., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
18. DiFiglia M. Huntingtin fragments that aggregate go their separate ways. Mol Cell 10 (2002) 224
19. DiFiglia M., Sapp E., Chase K., et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14 (1995) 1075-1081
20. DiFiglia M., Sapp E., Chase K.O., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
21. Dragatsis I., Levine M.S., and Zeitlin S. Inactivation of hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26 (2000) 300-306
22. Dunah A.W., Jeong H., Griffin A., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296 (2002) 2238-2243
23. Duyao M.P., Auerbach A.B., Ryan A., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269 (1995) 407-410
24. Engelender S., Sharp A.H., Colomer V., et al. Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin. Hum Mol Genet 6 (1997) 2205-2212
25. Faber P.W., Barnes G.T., Srinidhi J., et al. Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet 7 (1998) 1463-1474
26. Fusco F.R., Chen Q., Lamoreaux W.J., et al. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci 19 (1999) 1189-1202
27. Gafni J., Hermel E., Young J.E., et al. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279 (2004) 20211-20220
28. Gallo K.A., and Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 3 (2002) 663-672
29. Garcia M., Vanhoutte P., Pages C., et al. The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. J Neurosci 22 (2002) 2174-2184
30. Garcia M., Charvin D., and Caboche J. Expanded huntingtin activates the c-jun N-terminal kinase/c-jun pathway prior to aggregate formation in striatal neurons in culture. Neuroscience 127 (2004) 859-870
31. Gauthier L.R., Charrin B.C., Borrell-Pages M., et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118 (2004) 127-138
32. Gervais F.G., Singaraja R., Xanthoudakis S., et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 4 (2002) 95-105
33. Goldberg Y.P., Nicholson D.W., Rasper D.M., et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 13 (1996) 442-449
34. Grunewald T., and Beal M.F. Bioenergetics in Huntington's disease. Ann N Y Acad Sci 893 (1999) 203-213
35. Gunawardena S., Her L.S., Brusch R.G., et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyq proteins in Drosophila. Neuron 40 (2003) 25-40
36. Gutekunst C.A., Levey A.I., Heilman C.J., et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci U S A 92 (1995) 8710-8714
37. Gutekunst C.A., Li S.H., Yi H., et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19 (1999) 2522-2534
38. Hackam A.S., Yassa A.S., Singaraja R., et al. Huntingtin interacting protein 1 (HIP-1) induces apoptosis via a novel caspase-dependent death effector domain. J Biol Chem 275 (2000) 41299-41308
39. Harjes P., and Wanker E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28 (2003) 425-433
40. HD Coll. Res. Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
41. Hermel E., Gafni J., Propp S.S., et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 11 (2004) 424-438
42. Ho L.W., Brown R., Maxwell M., et al. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease. J Med Genet 38 (2001) 450-452
43. Hodgson J.G., Agopyan N., Gutekunst C.A., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
44. Hoffner G., Kahlem P., and Djian P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J Cell Sci 115 (2002) 941-948
45. Hoogeveen A.T., Willemsen R., Meyer N., et al. Characterization and localization of the Huntington disease gene product. Hum Mol Genet 2 (1993) 2069-2073
46. Humbert S., Bryson E.A., Cordelieres F.P., et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2 (2002) 831-837
47. Jana N.R., Zemskov E.A., Wang G., et al. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10 (2001) 1049-1059
48. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002) 1911-1912
49. Kalchman M.A., Koide H.B., McCutcheon K., et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet 16 (1997) 44-53
50. Kegel K.B., Meloni A.R., Yi Y., et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 277 (2002) 7466-7476
51. Kegel K.B., Sapp E., Yoder J., et al. Huntingtin associates with acidic phospholipids at the plasma membrane. J Biol Chem 280 (2005) 36464-36473
52. Kim M., Lee H.S., LaForet G., et al. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 19 (1999) 964-973
53. Kim M.J., Jo D.G., Hong G.S., et al. Calpain-dependent cleavage of cain/cabin1 activates calcineurin to mediate calcium-triggered cell death. Proc Natl Acad Sci U S A 99 (2002) 9870-9875
54. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81 (2001) 807-869
55. Laforet G.A., Sapp E., Chase K., et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 21 (2001) 9112-9123
56. Leavitt B.R., Guttman J.A., Hodgson J.G., et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 68 (2001) 313-324
57. Lee W.C., Yoshihara M., and Littleton J.T. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci U S A 101 (2004) 3224-3229
58. Li S.H., and Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20 (2004) 146-154
59. Li X.J., and Li S.H. HAP1 and intracellular trafficking. Trends Pharmacol Sci 26 (2005) 1-3
60. Li X.J., Li S.H., Sharp A.H., et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378 (1995) 398-402
61. Li S.H., Gutekunst C.A., Hersch S.M., et al. Interaction of huntingtin-associated protein with dynactin P150Glued. J Neurosci 18 (1998) 1261-1269
62. Li S.H., Cheng A.L., Li H., et al. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin. J Neurosci 19 (1999) 5159-5172
63. Li H., Li S.H., Johnston H., et al. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25 (2000) 385-389
64. Li S.H., Cheng A.L., Zhou H., et al. Interaction of huntington disease protein with transcriptional activator sp1. Mol Cell Biol 22 (2002) 1277-1287
65. Liu Y.F. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem 273 (1998) 28873-28877
66. Liu Y.F., Deth R.C., and Devys D. SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. J Biol Chem 272 (1997) 8121-8124
67. Liu C.Y., Schroder M., and Kaufman R.J. Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J Biol Chem 275 (2000) 24881-24885
68. Liu Y.F., Dorow D., and Marshall J. Activation of MLK2-mediated signaling cascades by polyglutamine- expanded huntingtin. J Biol Chem 275 (2000) 19035-19040
69. Lunkes A., Lindenberg K.S., Ben-Haiem L., et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10 (2002) 259-269
70. Luo S., Vacher C., Davies J.E., et al. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol 169 (2005) 647-656
71. Luthi-Carter R., Strand A., Peters N.L., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9 (2000) 1259-1271
72. McGuire J.R., Rong J., Li S.H., et al. Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J Biol Chem 281 (2006) 3552-3559
73. Mende-Mueller L.M., Toneff T., Hwang S.R., et al. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. J Neurosci 21 (2001) 1830-1837
74. Meriin A.B., Mabuchi K., Gabai V.L., et al. Intracellular aggregation of polypeptides with expanded polyglutamine domain is stimulated by stress-activated kinase MEKK1. J Cell Biol 153 (2001) 851-864
75. Michalik A., and Van Broeckhoven C. Proteasome degrades soluble expanded polyglutamine completely and efficiently. Neurobiol Dis 16 (2004) 202-211
76. Milakovic T., and Johnson G.V. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280 (2005) 30773-30782
77. Modregger J., DiProspero N.A., Charles V., et al. PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum Mol Genet 11 (2002) 2547-2558
78. Nasir J., Floresco S.B., O'Kusky J.R., et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81 (1995) 811-823
79. Nishitoh H., Saitoh M., Mochida Y., et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 2 (1998) 389-395
80. Nishitoh H., Matsuzawa A., Tobiume K., et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 16 (2002) 1345-1355
81. Nucifora Jr. F.C., Sasaki M., Peters M.F., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291 (2001) 2423-2428
82. Panov A.V., Gutekunst C.A., Leavitt B.R., et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5 (2002) 731-736
83. Pardo R., Colin E., Regulier E., et al. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci 26 (2006) 1635-1645
84. Peters M.F., Nucifora Jr. F.C., Kushi J., et al. Nuclear targeting of mutant Huntingtin increases toxicity. Mol Cell Neurosci 14 (1999) 121-128
85. Phelan D.R., Price G., Liu Y.F., et al. Activated JNK phosphorylates the c-terminal domain of MLK2 that is required for MLK2-induced apoptosis. J Biol Chem 276 (2001) 10801-10810
86. Rangone H., Humbert S., and Saudou F. Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?. Pathol Biol (Paris) 52 (2004) 338-342
87. Rangone H., Poizat G., Troncoso J., et al. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 19 (2004) 273-279
88. Rangone H., Pardo R., Colin E., et al. Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits polyq-huntingtin-induced toxicity by rescuing proteasome impairment. J Biol Chem 280 (2005) 22021-22028
89. Rigamonti D., Bauer J.H., De-Fraja C., et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20 (2000) 3705-3713
90. Rigamonti D., Sipione S., Goffredo D., et al. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 276 (2001) 14545-14548
91. Sapp E., Penney J., Young A., et al. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 58 (1999) 165-173
92. Saudou F., Finkbeiner S., Devys D., et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95 (1998) 55-66
93. Schaffar G., Breuer P., Boteva R., et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 15 (2004) 95-105
94. Schilling G., Sharp A.H., Loev S.J., et al. Expression of the Huntington's disease (IT15) protein product in HD patients. Hum Mol Genet 4 (1995) 1365-1371
95. Sharp A.H., Loev S.J., Schilling G., et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 14 (1995) 1065-1074
96. Sherman M.Y., and Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29 (2001) 15-32
97. Singaraja R.R., Hadano S., Metzler M., et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet 11 (2002) 2815-2828
98. Sisodia S.S. Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial?. Cell 95 (1998) 1-4
99. Snell R.G., MacMillan J.C., Cheadle J.P., et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 4 (1993) 393-397
100. Song C., Perides G., and Liu Y.F. Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem 277 (2002) 6703-6707
101. Steffan J.S., Kazantsev A., Spasic-Boskovic O., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97 (2000) 6763-6768
102. St-Pierre J., Drori S., Uldry M., et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127 (2006) 397-408
103. Sugars K.L., and Rubinsztein D.C. Transcriptional abnormalities in Huntington's disease. Trends Genet 19 (2003) 233-238
104. Szebenyi G., Morfini G.A., Babcock A., et al. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40 (2003) 41-52
105. Tang T.S., Tu H., Chan E.Y., et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39 (2003) 227-239
106. Tang T.S., Slow E., Lupu V., et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 102 (2005) 2602-2607
107. Trettel F., Rigamonti D., Hilditch-Maguire P., et al. Dominant phenotypes produced by the HD mutation in sthdh(Q111) striatal cells. Hum Mol Genet 9 (2000) 2799-2809
108. Trottier Y., Devys D., Imbert G., et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 10 (1995) 104-110
109. Trushina E., Dyer R.B., Badger II J.D., et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 24 (2004) 8195-8209
110. Vaudry D., Stork P.J., Lazarovici P., et al. Signaling pathways for PC12 cell differentiation: making the right connections. Science 296 (2002) 1648-1649
111. Velier J., Kim M., Schwarz C., et al. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp Neurol 152 (1998) 34-40
112. Venkatraman P., Wetzel R., Tanaka M., et al. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14 (2004) 95-104
113. Verhoef L.G., Lindsten K., Masucci M.G., et al. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 11 (2002) 2689-2700
114. Waelter S., Boeddrich A., Lurz R., et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12 (2001) 1393-1407
115. Wanker E.E., Rovira C., Scherzinger E., et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 6 (1997) 487-495
116. Warby S.C., Chan E.Y., Metzler M., et al. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 14 (2005) 1569-1577
117. Wellington C.L., Singaraja R., Ellerby L., et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem 275 (2000) 19831-19838
118. Weston C.R., and Davis R.J. The JNK signal transduction pathway. Curr Opin Genet Dev 12 (2002) 14-21
119. Weston C.R., Lambright D.G., and Davis R.J. Signal transduction. MAP kinase signaling specificity. Science 296 (2002) 2345-2347
120. Weydt P., Pineda V.V., Torrence A.E., et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 4 (2006) 349-362
121. White J.K., Auerbach W., Duyao M.P., et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17 (1997) 404-410
122. Whitmarsh A.J., and Davis R.J. Signal transduction by MAP kinases: regulation by phosphorylation-dependent switches. Sci STKE 1999 (1999) PE1
123. Wood J.D., MacMillan J.C., Harper P.S., et al. Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain. Hum Mol Genet 5 (1996) 481-487
124. Xia J., Lee D.H., Taylor J., et al. Huntingtin contains a highly conserved nuclear export signal. Hum Mol Genet 12 (2003) 1393-1403
125. Yasuda S., Inoue K., Hirabayashi M., et al. Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies. Genes Cells 4 (1999) 743-756
126. Yu Z.X., Li S.H., Nguyen H.P., et al. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Mol Genet 11 (2002) 905-914
127. Zeitlin S., Liu J.P., Chapman D.L., et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11 (1995) 155-163
128. Zeron M.M., Hansson O., Chen N., et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
129. Zhang Y., Li M., Drozda M., et al. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem 87 (2003) 101-106
130. Zuccato C., Ciammola A., Rigamonti D., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293 (2001) 493-498
131. Zuccato C., Tartari M., Crotti A., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35 (2003) 76-83